Article Text

Download PDFPDF

Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers
  1. Emma Beard1,
  2. Ann McNeill2,
  3. Paul Aveyard3,
  4. Jenny Fidler1,
  5. Susan Michie4,
  6. Robert West1
  1. 1Cancer Research UK Health Behaviour Research Centre, University College London, London, UK
  2. 2UK Centre for Tobacco Control Studies, City Hospital, Nottingham, UK
  3. 3Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
  4. 4University College London Research Department of Clinical, Educational and Health Psychology, University College London, London, UK
  1. Correspondence to Emma Beard, Cancer Research UK Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK; e.beard{at}ucl.ac.uk

Footnotes

  • Funding This study was funded by the English Department of Health, Cancer Research UK, Pfizer, GlaxoSmithKlein and Johnson and Johnson, who had no involvement in the design of the study, the analysis or interpretation of the data, the writing of the report or the decision to submit the paper for publication.

  • Competing interests PA has undertaken consultancy work on smoking cessation for Celtic (Xenova), Pfizer and McNeil. EB has received conference funding from Pfizer. RW undertakes research and consultancy and receives fees for speaking from companies that develop and manufacture smoking cessation medications. He also has a share of a patent for a novel nicotine delivery device.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by UCL.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This study was funded by the English Department of Health, Cancer Research UK, Pfizer, GlaxoSmithKlein and Johnson and Johnson, who had no involvement in the design of the study, the analysis or interpretation of the data, the writing of the report or the decision to submit the paper for publication.

  • Competing interests PA has undertaken consultancy work on smoking cessation for Celtic (Xenova), Pfizer and McNeil. EB has received conference funding from Pfizer. RW undertakes research and consultancy and receives fees for speaking from companies that develop and manufacture smoking cessation medications. He also has a share of a patent for a novel nicotine delivery device.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by UCL.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.